| Rhodanine as a privileged scaffold in drug discovery T Tomasic, LP Masic Current Medicinal Chemistry 16 (13), 1596-1629, 2009 | 347 | 2009 |
| Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation T Tomašić, L Peterlin Mašič Expert opinion on drug discovery 7 (7), 549-560, 2012 | 200 | 2012 |
| Efflux pump inhibitors of clinically relevant multidrug resistant bacteria A Lamut, L Peterlin Mašič, D Kikelj, T Tomašič Medicinal Research Reviews 39 (6), 2460-2504, 2019 | 182 | 2019 |
| Discovery of benzothiazole scaffold-based DNA gyrase B inhibitors M Gjorgjieva, T Tomasic, M Barancokova, S Katsamakas, J Ilas, ... Journal of medicinal chemistry 59 (19), 8941-8954, 2016 | 142 | 2016 |
| Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases T Tomašić, L Peterlin Masic Current topics in medicinal chemistry 14 (1), 130-151, 2014 | 139 | 2014 |
| Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site T Tomasic, S Katsamakas, Z Hodnik, J Ilaš, M Brvar, T Solmajer, ... Journal of medicinal chemistry 58 (14), 5501-5521, 2015 | 136 | 2015 |
| Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted … A Šmelcerović, K Tomović, Ž Šmelcerović, Ž Petronijević, G Kocić, ... European journal of medicinal chemistry 135, 491-516, 2017 | 126 | 2017 |
| Discovery of novel 5-benzylidenerhodanine and 5-benzylidenethiazolidine-2, 4-dione inhibitors of MurD ligase N Zidar, T Tomašić, R Šink, V Rupnik, A Kovac, S Turk, D Patin, ... Journal of medicinal chemistry 53 (18), 6584-6594, 2010 | 125 | 2010 |
| 5‐Benzylidenethiazolidin‐4‐ones as multitarget inhibitors of bacterial Mur ligases T Tomašić, N Zidar, A Kovač, S Turk, M Simčič, D Blanot, ... ChemMedChem: Chemistry Enabling Drug Discovery 5 (2), 286-295, 2010 | 94 | 2010 |
| Synthesis and antibacterial activity of 5-ylidenethiazolidin-4-ones and 5-benzylidene-4, 6-pyrimidinediones T Tomašić, N Zidar, M Mueller-Premru, D Kikelj, LP Mašič European Journal of Medicinal Chemistry 45 (4), 1667-1672, 2010 | 88 | 2010 |
| N-Phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATP Competitive DNA Gyrase B Inhibitors: Design, Synthesis, and Evaluation N Zidar, H Macut, T Tomasic, M Brvar, S Montalvao, P Tammela, ... Journal of medicinal chemistry 58 (15), 6179-6194, 2015 | 69 | 2015 |
| ATP-binding site of bacterial enzymes as a target for antibacterial drug design V Škedelj, T Tomašić, LP Mašič, A Zega Journal of medicinal chemistry 54 (4), 915-929, 2011 | 69 | 2011 |
| Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents J Fedorowicz, J Sączewski, A Konopacka, K Waleron, D Lejnowski, ... European Journal of Medicinal Chemistry 179, 576-590, 2019 | 68 | 2019 |
| Synthesis and Evaluation of N‐Phenylpyrrolamides as DNA Gyrase B Inhibitors M Durcik, P Tammela, M Barančoková, T Tomašič, J Ilaš, D Kikelj, N Zidar ChemMedChem 13 (2), 186-198, 2018 | 67 | 2018 |
| Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors Ž Jakopin, J Ilaš, M Barančoková, M Brvar, P Tammela, MS Dolenc, ... European Journal of Medicinal Chemistry 130, 171-184, 2017 | 67 | 2017 |
| Benzothiazole-based compounds in antibacterial drug discovery M Gjorgjieva, T Tomašič, D Kikelj, LP Mašič Current medicinal chemistry 25 (38), 5218-5236, 2018 | 65 | 2018 |
| Antioxidant and anti-inflammatory properties of 1, 2, 4-oxadiazole analogs of resveratrol M Gobec, T Tomašič, T Markovič, I Mlinarič-Raščan, MS Dolenc, ... Chemico-Biological Interactions 240, 200-207, 2015 | 63 | 2015 |
| Synthesis and biological evaluation of new glutamic acid-based inhibitors of MurD ligase T Tomašić, N Zidar, V Rupnik, A Kovač, D Blanot, S Gobec, D Kikelj, ... Bioorganic & Medicinal Chemistry Letters 19 (1), 153-157, 2009 | 62 | 2009 |
| ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents M Durcik, T Tomašič, N Zidar, A Zega, D Kikelj, LP Mašič, J Ilaš Expert opinion on therapeutic patents 29 (3), 171-180, 2019 | 61 | 2019 |
| Dual Inhibitor of MurD and MurE Ligases from Escherichia coli and Staphylococcus aureus T Tomašić, R Sink, N Zidar, A Fic, C Contreras-Martel, A Dessen, ... ACS Medicinal Chemistry Letters 3 (8), 626-630, 2012 | 61 | 2012 |
Lucija Peterlin MašičProffesor of medicinal chemistry and toxicologyVerifierad e-postadress på ffa.uni-lj.si
